Prostate cancer (PC) remains one of the most spread tumors worldwide and it is included in the top five of cancer death among men. While therapeutic approaches exist, some forms of PC –such as advanced and metastatic forms– continue to be a challenge for the modern medicine, leading research towards novel molecular targets. Among the emerging candidates, Fatty Acid-Binding Protein 12 (FABP12) has attracted attention because of its overexpression in metastatic cancer tissues and its involvement in lipid metabolism reprogramming and epithelial-to-mesenchymal transition (EMT). However, no selective FABP12 inhibitors have been developed and the lack of a crystalized structure for this protein results in a significant challenge for a structure-based drug design pipeline.